X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (72985) 72985
Newspaper Article (4896) 4896
Newsletter (4702) 4702
Magazine Article (471) 471
Book Chapter (348) 348
Book / eBook (106) 106
Dissertation (88) 88
Publication (74) 74
Conference Proceeding (52) 52
Web Resource (51) 51
Trade Publication Article (44) 44
Book Review (20) 20
Streaming Video (15) 15
Transcript (10) 10
Reference (8) 8
Government Document (7) 7
Paper (4) 4
Report (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49834) 49834
thromboembolism (42999) 42999
female (28193) 28193
male (23842) 23842
venous thromboembolism (19574) 19574
middle aged (19268) 19268
risk factors (16559) 16559
aged (16346) 16346
thrombosis (15550) 15550
adult (15516) 15516
hematology (11085) 11085
anticoagulants (10266) 10266
anticoagulants - therapeutic use (9778) 9778
surgery (9157) 9157
peripheral vascular disease (9016) 9016
prevention (8363) 8363
thromboembolism - prevention & control (8257) 8257
thromboembolism - etiology (8001) 8001
research (7899) 7899
risk (7889) 7889
pulmonary embolism (7387) 7387
deep-vein thrombosis (6402) 6402
cardiac & cardiovascular systems (6320) 6320
medicine, general & internal (6235) 6235
aged, 80 and over (6174) 6174
retrospective studies (6033) 6033
patients (5980) 5980
treatment outcome (5970) 5970
stroke (5694) 5694
health risk assessment (5673) 5673
mortality (5533) 5533
care and treatment (5483) 5483
warfarin (5043) 5043
cancer (4966) 4966
adolescent (4856) 4856
medical research (4642) 4642
analysis (4592) 4592
anticoagulants - administration & dosage (4538) 4538
venous thrombosis (4494) 4494
pulmonary-embolism (4397) 4397
diagnosis (4375) 4375
abridged index medicus (4348) 4348
pregnancy (4258) 4258
anticoagulants - adverse effects (4124) 4124
health aspects (4102) 4102
incidence (4081) 4081
management (4063) 4063
medicine, experimental (4060) 4060
atrial fibrillation (3997) 3997
venous thromboembolism - prevention & control (3975) 3975
risk assessment (3958) 3958
prospective studies (3955) 3955
time factors (3785) 3785
molecular-weight heparin (3768) 3768
risk-factors (3706) 3706
complications (3697) 3697
prophylaxis (3594) 3594
follow-up studies (3549) 3549
therapy (3542) 3542
drug therapy (3375) 3375
animals (3315) 3315
medicine & public health (3300) 3300
heparin (3210) 3210
anticoagulation (3208) 3208
cardiovascular diseases (3201) 3201
disease (3096) 3096
thromboembolism - drug therapy (3086) 3086
venous thromboembolism - etiology (2988) 2988
postoperative complications - prevention & control (2825) 2825
young adult (2803) 2803
deep vein thrombosis (2780) 2780
embolisms (2736) 2736
prognosis (2731) 2731
oncology (2705) 2705
hemorrhage - chemically induced (2613) 2613
thromboembolism - epidemiology (2583) 2583
heparin - therapeutic use (2558) 2558
cardiology (2544) 2544
administration, oral (2507) 2507
venous thromboembolism - epidemiology (2507) 2507
prevalence (2501) 2501
medicine (2454) 2454
recurrence (2440) 2440
embolism (2403) 2403
clinical trials (2400) 2400
studies (2389) 2389
bleeding (2314) 2314
child (2314) 2314
venous thrombosis - etiology (2312) 2312
hospitals (2292) 2292
pharmacology & pharmacy (2285) 2285
venous thrombosis - prevention & control (2284) 2284
rivaroxaban (2279) 2279
thromboprophylaxis (2278) 2278
coagulation (2276) 2276
hypertension (2258) 2258
enoxaparin (2207) 2207
veins & arteries (2145) 2145
hemorrhage (2139) 2139
heparin, low-molecular-weight - therapeutic use (2137) 2137
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (66) 66
Online Resources - Online (38) 38
Scarborough Hospital - Online (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Toronto East General Hospital - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (74930) 74930
German (3003) 3003
French (1998) 1998
Spanish (1026) 1026
Russian (1001) 1001
Japanese (722) 722
Italian (580) 580
Portuguese (348) 348
Polish (303) 303
Chinese (295) 295
Czech (245) 245
Korean (156) 156
Danish (125) 125
Hungarian (113) 113
Turkish (108) 108
Swedish (103) 103
Dutch (96) 96
Norwegian (74) 74
Croatian (51) 51
Bulgarian (48) 48
Romanian (44) 44
Slovak (40) 40
Hebrew (38) 38
Serbian (36) 36
Finnish (27) 27
Ukrainian (18) 18
Slovenian (16) 16
Persian (10) 10
Lithuanian (6) 6
Estonian (3) 3
Icelandic (3) 3
Afrikaans (2) 2
Arabic (1) 1
Bosnian (1) 1
Georgian (1) 1
Indonesian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of vascular surgery, ISSN 0741-5214, 08/2017, Volume 66, Issue 2, pp. e32 - e33
Journal Article
American Journal of Clinical Pathology, ISSN 0002-9173, 09/2013, Volume 140, Issue suppl_1, pp. A225 - A225
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
no | Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 8, pp. 709 - 718
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 23, pp. 2167 - 2177
In this clinical trial of hospitalized medically ill patients, extended thromboprophylaxis (30 days) with apixaban had similar efficacy to that of a shorter... 
REPLACEMENT | MEDICINE, GENERAL & INTERNAL | VENOUS THROMBOEMBOLISM | PULMONARY-EMBOLISM | DOUBLE-BLIND | PREVENTION | PLACEBO-CONTROLLED TRIAL | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thromboembolism - epidemiology | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Drug Administration Schedule | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Heart Failure - drug therapy | Pulmonary Embolism - mortality | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Respiratory Insufficiency - drug therapy | Drugs | Enoxaparin | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Thrombolytic drugs | Comparative analysis | Drug therapy | Heart failure | Fees & charges | Anticoagulants | Compression | Prophylaxis | Congestive heart failure | Thrombosis | Bleeding | Embolism | Compression therapy | Ultrasonic imaging | Hospitals | Safety | Thromboembolism | Health risk assessment | Ultrasound | Respiratory Insufficiency | Hemorrhage | Life Sciences | Venous Thromboembolism | Heart Failure | Pyrazoles | Pyridones | Human health and pathology | Pulmonary Embolism
Journal Article
Journal Article
1972, 1st ed., 194
Book
Contraception, ISSN 0010-7824, 2013, Volume 87, Issue 1, pp. 93 - 100
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2017, Volume 15, Issue 10, pp. 1963 - 1970
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
The Journal of heart and lung transplantation, ISSN 1053-2498, 04/2020, Volume 39, Issue 4, pp. S190 - S190
The CorWave LVAD employs a unique “wave membrane” technology, inspired from the motion of aquatic animals, to generate blood flow. This low shear method of... 
Thromboembolism
Journal Article
Thrombosis research, ISSN 0049-3848, 07/2020, Volume 191, pp. 153 - 155
•Hypercoagulability is a major contributor to COVID-19 related pulmonary complications•Commonly used approaches may be insufficient to ameliorate the risk of... 
Thromboembolism
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2013, Volume 11, Issue 1, pp. 56 - 70
Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal... 
Clinical practice guidelines | Anticoagulant | GRADE system | Bleeding | Venous thromboembolism | Cancer | DEEP-VEIN THROMBOSIS | SECONDARY PREVENTION | PERIOPERATIVE THROMBOPROPHYLAXIS | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | PERIPHERAL VASCULAR DISEASE | COMPRESSION STOCKINGS | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | LONG-TERM TREATMENT | VENA-CAVA FILTERS | UNFRACTIONATED HEPARIN | Recurrence | Humans | Antineoplastic Agents - therapeutic use | Venous Thromboembolism - drug therapy | Patient Selection | Fibrinolytic Agents - adverse effects | Neoplasms - complications | Venous Thromboembolism - prevention & control | Neoplasms - blood | Time Factors | Fibrinolytic Agents - therapeutic use | Venous Thromboembolism - diagnosis | Risk Assessment | Risk Factors | Cooperative Behavior | Benchmarking | Treatment Outcome | International Cooperation | Evidence-Based Medicine | Consensus | Vena Cava Filters | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Thrombolytic Therapy | Hemorrhage - chemically induced | Medical colleges | Aspirin | Glycosaminoglycans | Brain tumors | Leukemia | Oncology, Experimental | Practice guidelines (Medicine) | Laparoscopic surgery | Anticoagulants (Medicine) | Laparoscopy | Transplantation | Metastasis | Research | Pulmonary embolism | Blood circulation disorders | Cancer patients | Chemotherapy | Bone marrow | Adults | Drug therapy | Health aspects | Public health | Clinical medicine | Patients
Journal Article